Gefticip 250 mg

Gefticip 250mg Tablet is an antineoplastic medication classified as a tyrosine kinase inhibitor, with Gefitinib as its active component. It is indicated for the treatment of non-small cell lung cancer (NSCLC). NSCLC is characterized by the uncontrolled and abnormal proliferation of cells within lung tissues. This medication is prescribed for patients whose NSCLC has metastasized to other areas of the body, particularly those with specific mutations in the epidermal growth factor receptor (EGFR) genes, and for individuals who have not previously undergone cancer treatment.

Certain formulations of this medication may include lactose as an inactive ingredient, which the body cannot digest. Lactose is a sugar present in milk and dairy products and may lead to symptoms such as bloating and abdominal discomfort. If you are lactose intolerant, it is essential to inform your physician prior to initiating this treatment. Additionally, consult your healthcare provider if you have kidney or liver issues, vision impairments, lung conditions, or if you are taking anticoagulants like warfarin. Regular blood tests will be conducted by your healthcare provider to monitor for potential complications. It is advisable to refrain from alcohol consumption as it may induce dizziness.

Before using this medication, consult your physician if you are pregnant or planning to conceive. These tablets are contraindicated during pregnancy due to the potential harm they may cause to an unborn child. Your healthcare provider will perform a pregnancy test prior to commencing treatment with this tablet. Discuss effective contraceptive methods with your doctor and ensure their use for at least two weeks after the final dose. It is also recommended to avoid breastfeeding while undergoing this treatment, as it is unclear whether this drug is excreted in breast milk.